CBD and Parkinson’s Disease

Peer-reviewed studies into the potential effects of Cannabidiol and Parkinson’s Disease

On this page, CBD and Parkinson’s Disease, you will find research pertaining to the use of Cannabidiol and Cannabinoids and its possible effects on Parkinson’s Disease. The information below is not meant to influence your opinion, but rather give you access to a wealth of scientific literature in an attempt to make and educated and informed choice. Click Here to see all of the conditions that have been researched alongside CBD and Parkinson’s Disease.

 

Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial.

From the abstract:

Our findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives are required before definitive conclusions can be drawn.

Prospects for cannabinoid therapies in basal ganglia disorders.

From the abstract: 

…CB(2) receptor up-regulation has been found in many neurodegenerative disorders including [Huntington’s Disease (HD)] and [Parkinson’s Disease (PD)], which supports the beneficial effects found for CB(2) receptor agonists in both disorders. In conclusion, the evidence reported so far supports that those cannabinoids having antioxidant properties and/or capability to activate CB(2) receptors may represent promising therapeutic agents in HD and PD, thus deserving a prompt clinical evaluation.

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: Importance of antioxidant cannabinoid receptor-independent properties

From the abstract:

We have recently demonstrated that two plant-derived cannabinoids, Delta9-tetrahydrocannabinol and cannabidiol (CBD), are neuroprotective in an animal model of Parkinson’s disease (PD), presumably because of their antioxidant properties. To further explore this issue, we examined the neuroprotective effects of a series of cannabinoid-based compounds… the effect of CBD implied an upregulation of mRNA levels for Cu,Zn-superoxide dismutase, a key enzyme in endogenous defenses against oxidative stress. In summary, our results indicate that those cannabinoids having antioxidant cannabinoid receptor-independent properties provide neuroprotection against the progressive degeneration of nigrostriatal dopaminergic neurons occurring in PD.

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.

From the abstract:

…our results support the view of a potential neuroprotective action of cannabinoids against the in vivo and in vitro toxicity of 6-hydroxydopamine, which might be relevant for [Parkinson’s Disease]. Our data indicated that these neuroprotective effects might be due, among others, to the antioxidant properties of certain plant-derived cannabinoids, or exerted through the capability of cannabinoid agonists to modulate glial function, or produced by a combination of both mechanisms. 

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series.

From the abstract:

Cannabidiol (CBD) is the main non-psychotropic component of the Cannabis sativa plant. REM sleep behaviour disorder (RBD) is a parasomnia characterized by the loss of muscle atonia during REM sleep associated with nightmares and active behaviour during dreaming. We have described the effects of CBD in RBD symptoms in patients with Parkinson’s disease… Four patients treated with CBD had prompt and substantial reduction in the frequency of RBD-related events without side effects…This case series indicates that CBD is able to control the symptoms of RBD.

Cannabidiol for the treatment of psychosis in Parkinson’s disease.

From the abstract:

The psychotic symptoms evaluated by the Brief Psychiatric Rating Scale and the Parkinson Psychosis Questionnaire showed a significant decrease under CBD treatment. CBD did not worsen the motor function and decreased the total scores of the Unified Parkinson’s Disease Rating Scale. No adverse effect was observed during the treatment. These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in [Parkinson’s Disease].

Therapeutic potential of cannabidnoids in CNS disease.

From the abstract:

This review highlights recent advances in understanding of the endocannabinoid system and indicates CNS disorders that may benefit from the therapeutic effects of cannabinoid treatment. Where applicable, reference is made to ongoing clinical trials of cannabinoids to alleviate symptoms of these disorders.

Neurological Aspects of Medical Use of Cannabidiol.

From the abstract:

[Cannabidiol] neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases… Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, but its employment for these disorders needs further confirmation from well designed clinical studies.